Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) Director Kevin D. Freeman acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average price of $2.70 per share, for a total transaction of $13,500.00. Following the completion of the purchase, the director now owns 33,469 shares in the company, valued at $90,366.30. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Galectin Therapeutics Stock Performance
Shares of GALT stock opened at $2.67 on Friday. The company has a market capitalization of $166.29 million, a PE ratio of -3.38 and a beta of 0.61. Galectin Therapeutics Inc. has a 52-week low of $1.55 and a 52-week high of $4.27. The business’s fifty day moving average is $2.59 and its 200 day moving average is $2.73.
Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). On average, sell-side analysts forecast that Galectin Therapeutics Inc. will post -0.79 EPS for the current fiscal year.
Institutional Investors Weigh In On Galectin Therapeutics
Analysts Set New Price Targets
GALT has been the topic of several analyst reports. StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research note on Friday, August 16th.
View Our Latest Report on GALT
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
See Also
- Five stocks we like better than Galectin Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Following Congress Stock Trades
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is the Nasdaq? Complete Overview with History
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.